recommend buy rate upgrad tp
previous deriv tp base
estim ep forward price-to-earnings multipl
give upsid potenti
expect top-lin revenu grow
estim base follow factor strong
growth across segment continu advanc
pipelin oncolog vaccin hospit specialti well
anim health balanc capit alloc
merck deliv top bottom line growth
quarter well posit finish year strong total
revenu increas net incom
ep increas
non-gaap ep increas
sale growth due higher sale oncolog
franchis reflect strong growth keytruda well
allianc revenu relat lynparza lenvima
revenu growth rate unfavor impact time
purchas well shorter flea tick season
gross margin compar
decreas due charg relat
termin collabor agreement samsung
pharmaceut segment revenu increas
increas due growth
oncolog hospit acut care
compani namemerck compani tickermrkstock ratingbuyunchangedindustri viewoverweightpositivepric week week volum volum ep margin margin ttm per share growth profit ttm ttm incom ttm earn growth yoy n/acrispideaakansha merck compani inc ember
incom statement
guidanc
non-
per share item
product perform develop
valuat consensu perform
growth oncolog due signific increas
sale keytruda reflect merck continu launch
new indic global strong momentum
treatment patient nsclc
result studi keytruda
combin axitinib met primari endpoint
overal surviv progression-fre surviv
vaccin busi also key pillar growth
growth sale gardasil
achiev sale demand continu
increas global merck continu advanc
program studi underway across
adult pediatr
hospit specialti medicin busi deliv strong
growth bridion sale increas y/i continu
experi strong demand
anim sale grew exclud impact
exchang livestock grew
companion anim grew quarter
current price-to-earnings
due increas stock price price-to-earnings
seen huge fluctuat past due volatil
stock price averag price-to-earnings
expect forward price-to-earnings multipl
recommend buy rate stock tp
expect merck grow base
perform
stock price histori date high obsolet date obsolet move move share statist averag volum averag volum share held held share short short share short prior month error dividend split forward annual dividend forward annual dividend trail annual dividend trail annual dividend year averag dividend pay-out dividend date jan ex-dividend date dec last split factor new per last split date feb inform merck compani inc novemb
incom statement
guidanc
non-
per share item
product perform develop
valuat consensu perform
non- reconcili refer page
incom statement item total gross research sale gener restructur merger total oper oper interest incom incom provis incom net incom continu net incom avail common weight averag share estim annual actual annual actual quarterli merck compani inc novemb
cash short-term total defer incom current total current net properti plant equiti intang long-term total non-curr total short-term account tax accru current total current non-curr liabilitieslong-term defer tax minor long-term total non-curr total common addit paid-in retain treasuri accumul comprehens total stockhold total liabil stockhold balanc sheet itemsactu annual actual quarterli merck compani inc novemb
provid oper activ increas period
compar reflect up-front payment made compani relat
format collabor eisia
provid invest activ declin period
compar declin due lower proce sale secur
invest higher capit expenditur well mileston payment
relat collabor bayer
use financ activ period compar
higher use cash financ activ due higher payment debt
higher purchas treasuri stock payment conting consider relat prior year
depreci investment/asset impair invest loss defer incom stock base chang work account account accru incom tax work non-cash net cash provid oper invest properti plant acquisit purchas sales/matur purchas invest net cash use invest debt debt common stock dividend financ net cash provid use financ effect exchang rate net chang begin end merck compani inc novemb
merck deliv strong perform quarter due key product
keytruda advanc pipelin
total sale increas compar
includ neg impact foreign exchang
sale growth period due higher sale oncolog franchis
reflect strong growth keytruda well allianc revenu relat
lynparza lenvima
sale increas attribut reduct sale
due borrow center diseas control
prevent cdc pediatr vaccin stockpil gardasil driven part
temporari product shutdown result cyber-attack
occur june sale unfavor affect
lost revenu certain market relat cyber-attack
total sale increas compar
total intern sale increas
compar total revenu europ
middl east africa declin compar
total sale increas
compar
impact foreign
total sale
increas
compar
geograph europ middl east asia latin merck compani inc novemb
total revenu asia pacif increas
compar total revenu japan decreas
compar total revenu
latin america decreas compar
total revenu region flat
gaap cog increas compar
non-gaap cog increas
compar cost includ aggreg
charg relat termin collabor agreement samsung
non-gaap gross margin compar
increas predominantli due favor effect foreign
exchang well cost record relat cyber-attack
gross margin compar
decreas gross margin due charg relat
termin collabor agreement samsung decreas
off-set favor effect foreign exchang well cost record
relat cyber-attack
sg expens compar
reflect lower direct sell promot cost well favor
effect foreign exchang larg off-set higher administr cost non-
market administr expens
compar
 expens decreas compar
declin reflect charg record
relat format collabor astrazeneca lower in-
process research develop ipr impair charg
cog increas
compar
compar
non-gaap expens increas compar
increas reflect higher clinic develop spend
particular oncolog higher licens cost invest discoveri
gaap ep increas
compar
compar
effect tax rate compar
net incom compar net loss
gaap ep increas compar
non-gaap ep compar
decreas
compar
period total revenu increas
compar period cog
increas compar
period sg expens increas
compar increas reflect higher administr cost
unfavor effect foreign exchang off-set lower promot
sell expens
period expens decreas
compar expens includ aggreg
charg relat format collabor eisai co ltd eisai
well charg acquisit viralyt limit
month period effect tax rate compar
period net incom increas
compar period ep increas
compar
merck oper two busi segment pharmaceut anim
compar
segment includ human health pharmaceut
vaccin product health pharmaceut product consist
therapeut prevent agent gener sold prescript
treatment human disord vaccin product consist prevent
pediatr adolesc adult vaccin primarili administ physician
pharmaceut segment revenu increas
compar period total
revenu increas compar
increas due growth oncolog hospit acut care
partial off-set lower sale virolog on-going impact loss
market exclus sever product
total revenu pharmaceut segment increas
compar total intern
revenu increas compar
growth oncolog due signific increas sale
keytruda reflect merck continu launch new indic
global strong momentum treatment patient nsclc
keytruda approv first-lin set
oncolog sale reflect allianc revenu relat lynparza
relat lenvima repres merck share profit
product sale net cost sale commerci cost
allianc revenu
relat lynparza
relat lenvima
profit
product sale net cost
sale
total revenu keytruda increas
compar period total
revenu increas compar
sale growth led volum growth market
continu launch multipl new indic global
total revenu keytruda increas
compar total intern revenu
increas compar
allianc revenu lynparza compar
period total revenu increas
compar
allianc revenu lenvima
period total revenu increas
vaccin perform reflect higher sale gardasil gardasil
vaccin prevent certain cancer diseas caus hpv
unit state attribut cdc stockpil borrow
growth intern market due higher sale europ
on-going commerci launch china
vaccin perform neg affect signific decreas
sale zostavax vaccin due approv competitor product
receiv preferenti recommend advisori committe
immun practic octob anticip futur sale
zostavax continu unfavor affect competit
total revenu
keytruda increas
compar
allianc revenu
lenvima
revenu increas
gardasil revenu increas compar
period total revenu
increas compar
increas
compar
increas due higher sale unit state attribut
borrow cdc pediatr vaccin stockpil increas
sale gardasil/gardasil also due higher demand
intern market particularli china due on-going launch
europ
gardasil revenu form increas
compar revenu increas
compar
proquad/m-m-r ii /varivax revenu increas
compar period total
revenu increas compar
proquad/m-m-r ii /varivax revenu increas
compar
revenu decreas compar
rotateq revenu increas compar
period total revenu increas
compar
rotateq revenu increas
compar total intern revenu increas
compar
increas
compar
compar
zostavax revenu declin compar
period total revenu declin
compar
sale declin due lower volum market particularli
unit state lower demand unit state reflect approv
competitor vaccin receiv preferenti recommend
cdc advisori committe immun practic octob
prevent shingl zostavax
zostavax revenu declin
compar total intern revenu declin
compar
growth hospit acut care reflect strong demand unit state
bridion inject mg/ml strong global demand noxafil
compar
bridion revenu increas compar
period total revenu increas
compar sale growth
period reflect volum growth unit state certain
bridion revenu increas
compar total intern revenu decreas
compar
noxafil revenu increas compar
period total revenu increas
compar sale growth
reflect higher demand unit state well volum growth
certain european market china
noxafil revenu increas
compar revenu increas
compar
noxafil revenu
 increas
compar
invanz revenu decreas compar
period total revenu decreas
compar declin
due lower volum
invanz revenu declin compar
total intern revenu declin
compar
declin
compar
cancida revenu declin compar
period total revenu declin
cancida revenu declin
compar total intern revenu declin
compar
simponi revenu declin compar
includ unfavor effect foreign exchang sale
declin reflect lower price partial off-set higher volum europ
period simponi revenu increas
compar includ favor effect
foreign exchang sale growth driven volum growth europ
remicad revenu declin compar
period total revenu
declin compar
foreign exchang unfavor affect global sale perform remicad
favor affect global sale perform
period merck lost market exclus
remicad major european market longer market
exclus market territori merck experienc price
volum declin market result biosimilar competit
expect declin continu
total revenu isentress isentress hd decreas
compar
month period total revenu decreas
compar sale declin due lower
demand unit state competit price pressur lower
volum europ
isentress/isentress hd revenu declin
compar total intern revenu
decreas compar
zepati revenu decreas compar
period total revenu
declin compar
sale declin due unfavor effect increas competit
declin patient volum particularli unit state europ
zepati revenu declin
compar total intern revenu declin
compar
total revenu
decreas
compar
decreas
compar
combin global sale zetia vytorin atozet rosuzet declin
compar previou year quarter
includ unfavor effect foreign exchang sale declin
due lower sale europ well unit state
sale declin reflect lower volum price zetia vytorin
unit state well certain european market result
gener competit declin partial off-set higher sale
japan due part launch atozet
januvia janumet
declin
compar
effect foreign
world-wide sale
nuvar increas
compar
world-wide combin sale januvia janumet declin
compar includ
unfavor effect foreign exchang period
global combin sale januvia janumet flat
compar prior-period sale perform reflect
continu price pressur particularli unit state partial off-set
higher demand global
world-wide sale nuvar increas
compar period total
revenu increas compar
sale growth due higher price unit state
patent provid market exclus nuvar expir april
nuvar revenu increas
compar total intern revenu declin
compar
implanon nexplanon revenu increas
compar period total
revenu increas compar
implanon nexplanon revenu increas
compar total intern revenu
increas compar
total revenu diversifi brand decreas
compar period
total revenu declin compar
anim segment includ pharmaceut vaccin product
prevent treatment control diseas major farm
anim sale increas compar
period total revenu increas
compar
anim revenu increas
compar total intern revenu increas
compar
sale growth due higher sale companion anim product
higher sale livestock product includ rumin poultri
total revenu
decreas
compar
increas
compar
total revenu livestock increas
compar period total
revenu increas compar
livestock revenu increas
compar total intern revenu decreas
compar
total revenu companion anim increas
compar period
total revenu increas compar
total revenu compar
total intern revenu decreas
compar
total revenu
livestock increas
compar
total revenu
increas
compar
oncolog pipelin highlight merck continu expand oncolog program
advanc develop program keytruda lynparza
merck announc base result trial
 fda european commiss ec approv keytruda
combin pemetrex platinum chemotherapi first-lin
treatment patient metastat non-squam non-smal cell lung
cancer nsclc egfr genom tumor aberr
merck announc fda grant prioriti review new
supplement biolog licens applic seek approv keytruda
monotherapi first-lin treatment local advanc metastat non-
squamou squamou nsclc patient whose tumor express
tumor proport score tp without egfr genom tumor
aberr base result pivot phase trial
fda set pdufa date jan
merck announc top-lin result pivot phase trial
studi keytruda combin axitinib first-lin
treatment advanc metastat renal cell carcinoma met
primari endpoint overal surviv os progression-fre surviv
demonstr combin made statist signific
clinic meaning improv surviv versu sunitinib
merck announc interim result pivot phase trial
studi keytruda monotherapi combin
chemotherapi first-lin treatment recurr metastat head
neck squamou cell carcinoma met primari endpoint
demonstr monotherapi combin therapi show
significantli improv os compar standard care
merck announc
base result
trial
 fda european
keytruda combin
pemetrex
result
studi keytruda
monotherapi
combin
merck announc first present result
phase trial evalu keytruda previously-tr patient
complet respons rate nearli
merck astrazeneca announc detail result phase
trial test lynparza mainten treatment patient newly-
diagnos advanc brca-mut ovarian cancer complet
result trial confirm statistically-signific clinically-
meaning improv lynparza compar placebo
reduc risk diseas progress death month
follow-up median patient treat lynparza reach
compar month patient treat placebo
merck eisai announc fda approv lenvima first-
line treatment patient unresect hepatocellular carcinoma
lenvima also approv use china china nation
drug administr europ ec
merck eisai announc fda grant breakthrough therapi
design lenvima combin keytruda potenti
treatment patient advanc and/or metastat non-microsatellit
instabl high/profici mismatch repair endometri carcinoma
progress follow least one prior system therapi third
breakthrough therapi design lenvima second breakthrough
therapi design lenvima combin keytruda
merck announc first
present result
keytruda previously-
treat patient high-
merck eisai announc
fda approv
lenvima first-lin
treatment patient
oncolog pipelin highlight clinic data merck earli pipelin
present esmo congress octob addit data
program present societi immunotherapi cancer
meet novemb
esmo merck present number dataset earli
sting agonist first-in-human data merck phase
program studi monotherapi combin keytruda
patient advanc solid tumor lymphoma
rig-i data merck phase trial studi advanc
recurr tumor
cavatak data merck phase trial studi
combin keytruda treatment nsclc bladder cancer
data merck phase trial studi
combin keytruda treatment advanc solid tumor
merck present
data merck phase trial studi
monotherapi combin keytruda treatment
tigit data merck phase trial studi
monotherapi combin keytruda treatment
patient solid tumor
rig-i data
studi advanc
data
studi monotherapi
combin
keytruda
treatment advanc
pipelin highlight merck also continu advanc vaccin
antibiot hiv pipelin
fda approv expand age indic gardasil use
women men age
merck announc pivot phase clinic studi evalu
compani antibiot zerbaxa investig dose treatment
adult patient either ventil hospital-acquir bacteri pneumonia
ventilator-associ bacteri pneumonia met pre-specifi primari
endpoint demonstr non-inferior meropenem activ
compar day all-caus mortal clinic cure rate test-
merck plan submit supplement new drug applic fda
ema seek regulatori approv zerbaxa potenti new
merck announc fda approv two new medicin indic
treatment infect adult patient prior
combin tablet doravirin mg lamivudin mg
tenofovir disoproxil fumar tdf mg pifeltro doravirin
mg new non-nucleosid revers transcriptas inhibitor administ
combin antiretrovir medicin
chmp ema adopt posit opinion recommend grant
market author delstrigo pifeltro treatment
adult infect without past present evid
resist non-nucleosid revers transcriptas class lamivudin
merck plan submit
applic fda
ema seek
regulatori approv
zerbaxa
chmp ema
recommend grant
delstrigo
pifeltro
treatment adult
clinic regulatori catalyst next month
/adjuv tnbc tnbc gastric bladder bladder msi-h esophag tnbc pancreat cancer combin studi rcc combin anti-tightfirst time data clinic merck compani inc novemb
clinic regulatori catalyst next month
cough patient urti infant data present cough failur hospital/specialti clinic lung merkel melanoma metastat breast cancer merck compani inc novemb
tabl show pipelin product develop differ phase
guidanc conclus
gaap ep expect
 non-
gaap ep expect
merck focu increas
across key busi
due higher demand
well invest
discoveri develop
oper
revenu expect
gaap ep expect non-gaap ep expect
tax rate expect non- tax rate
expect
merck deliv strong perform quarter growth
revenu ep non-
gaap ep sale growth due higher sale
oncolog franchis reflect strong growth keytruda well allianc
revenu relat lynparza lenvima
oncolog sale reflect allianc revenu relat lynparza
relat lenvima total revenu keytruda increas
anim sale increas sale growth
due higher sale companion anim product higher sale
livestock product includ rumin poultri product
merck announc increas quarterli dividend per outstand
share author addit share repurchas includ
acceler share repurchas program merck plan spend roughli
capit project
merck focu increas manufactur capac across key busi
due higher demand well invest discoveri develop
oper infrastructur
non- reconcili
non- reconcili
non- reconcili
incom statement
guidanc
non-
per share item
product perform develop
valuat consensu perform
gross margin declin ttm basi compar due increas
revenu growth ttm basi compar
oper margin increas ttm basi compar due increas
ratio revenu margin margin inc margin rate margin turnov averag asset leverag averag equiti year averag averag averag year averag averag averag year averag averag averag growth growth ex sale /sale /net incom ratio profit marginsprofitabilityrevenu growth oper incom growthep growth merck compani inc novemb
mrqgross mrqoper mrqnet mrqcog mrqsg mrqr sale merck compani inc novemb
invest flow
sale
mrqfinanci mrqreturn mrqreturn mrqyoy growth revenu growthoper incom growthep mrq ratio growth yoy oper growth yoy free growth mrqcapex salescap ex salesfre /sale merck compani inc novemb
per share item ratio
fiscal per ebitda per ebit per earn per share ep ep free flow per dividend per book valu per tangibl book per month end stock month end stock equiti return asset return invest capit return capit joel greenblatt debt gross margin oper margin net margin total equiti total lt debt total asset dividend pay-out day sale day account day convers inventori cog inventori tax rate net incom net incom discontinued- net net margin prefer dividends- annual itemsquarterli item merck compani inc novemb
balanc sheet item
outstand equival market debt common prefer stock- purchas properti plant sale properti plant equipment- purchas sale purchas sale issuanc stock- repurchas net issuanc prefer stock- net issuanc net chang capit free merck compani inc novemb
current price-to-earnings due increas stock price price-to-earnings
seen huge fluctuat past due volatil stock price averag price-to-earnings
expect forward price-to-earnings multipl
incom statement
guidanc
non-
per share item
product perform develop
valuat consensu perform
breakdown share held share held float held institut hold institut holdersholdersharesd report outvaluevanguard group inc capit world wellington manag compani jp morgan price row associ america top mutual fund holdersholdersharesd report outvaluevanguard total stock market vanguard washington mutual investor incom fund america spdr etf vanguard institut fund-institut vanguard specialized-health fidel american balanc ishar merck compani inc novemb
developmentsmerck keytruda pembrolizumab significantli improv overal surviv os compar chemotherapi patient advanc esophag esophagogastr junction carcinoma whose tumor express announc phase trial investig keytruda met primari endpoint overal surviv os patient whose tumor express combin posit score pivot studi treatment keytruda result statist signific improv os compar chemotherapi patient regardless histolog primari endpoint os also evalu patient squamou cell histolog entir intention-to-treat studi popul direct favor statist signific os met two patient group per statist analysi plan key secondari endpoint progression-fre surviv object respons rate orr formal test os reach full studi popul safeti profil keytruda trial consist observ previous report studi fda accept regulatori submiss lynparza olaparib mainten therapi newly-diagnos brca-mut advanc ovarian cancer grant prioriti reviewnovemb merck announc food drug administr fda accept supplement new drug applic snda prioriti review approv lynparza tablet mainten treatment patient newly-diagnos brca-mut brcam advanc ovarian cancer complet partial respons follow first-lin standard platinum-bas chemotherapi prescript drug user fee act pdufa date set data investig studi lenvima lenvatinib keytruda pembrolizumab combin three differ tumor type present societi immunotherapi cancer annual meetingnovemb co ltd merck announc result present new data analys lenvima lenvatinib oral avail kinas inhibitor discov eisai combin merck therapi keytruda three differ tumor type metastat non-smal cell lung cancer nsclc metastat melanoma metastat urotheli carcinoma merck hiv therapi delstrigo doravirin lamivudin tenofovir disoproxil fumar meet primari efficaci endpoint phase drive-shift studi evalu switch delstrigo antiretrovir treatment regimensnovemb announc first present data phase drive-shift trial evalu switch medic delstrigo once-daili fixed-dos combin tablet doravirin mg lamivudin mg tenofovir disoproxil fumar tdf mg adult infect demonstr virolog suppress least six month stabl antiretrovir treatment regimen studi met primari endpoint non-inferior efficaci measur proport particip switch delstrigo plasma rna level copies/ml week compar proport particip continu baselin regimen rna level copies/ml week merck compani inc novemb
incom statement
guidanc
non-
per share item
product perform develop
valuat consensu perform
vs
gross margin ttm
industri
averag
roa roe roi
actual vs price-to-earnings ratio ttm price-to-earnings high last yr price-to-earnings last yr beta price sale ttm price book mrq price ttm price free ttm errorerrorerror own dividend yield dividend yield year average dividend year growth rate pay-out ratio ttm sale mrq vs qtr yr sale ttm vs ttm yr sale yr growth rate sale yr growth rate ep mrq vs qtr yr ep ttm vs ttm yr ep yr growth rate ep yr growth rate capit spend yr growth rate lt debt equiti mrq total debt equiti mrq interest coverag ttm gross margin ttm gross margin yr average ebitd margin ttm ebitd yr average oper margin ttm oper margin yr average pre-tax margin ttm pre-tax margin yr average net profit margin ttm net profit margin yr average effect tax rate ttm effect tax rate yr average return asset ttm return asset yr average return invest ttm return invest yr average return equiti ttm return equiti yr average revenue/employe ttm net income/employe ttm receiv turnov ttm inventori turnov ttm asset turnov ttm manag effect effici performancevalu ratio dividend growth rate ratio profit merck compani inc novemb
consensu view analyst trend stock
forecast
lower
forward price-to-earnings
lower
mrk avgfive-year growth forecast usdgrowth high day day day estim comparisonmrkindustri avg avgprice/earn yield merck compani inc novemb
consensu view analyst trend stock
averag earn estim
current qtr
next qtr
sale growth estim current
qtr
next qtr
averag revenu estim
current qtr
estimatescurr analyst estimatethi estim estimatepast ep growthprice/earningsobsoleteobsoleteobsoleteobsoletepeg ratioobsoleteobsoleteobsoleteobsoleteconsensu ep day day day day ep last last last dayserrorerrorerrorerrordown last dayscurr surprisescurr growth rate analyst recommend
incom statement
guidanc
non-
per share item
product perform develop
valuat consensu perform
stock price volatil quarter show upward trend surg
merck gave return quarter averag daili volum share
stock price show upward trend last one year due advanc pipelin
stock gave return last rang stock
stock price surg septemb volatil till april
stock price surg novemb gave return past
merck deliv strong result quarter growth revenu growth due strong
perform keytruda advanc pipelin recommend buy rate stock base
perform period tp
crispidea financi inform servic firm focus provid equiti research portfolio manag
person wealth manag brokerag servic inform servic side provid commun
consult research servic host client
crispidea track limit number compani sector strive provid qualiti insight straight
forward analysi object creat long-term wealth moder low risk crispidea leverag
larg number in-hous extern expert oper within industri strong financi oper
strateg background
detail visit www crispidea com contact
